v3.20.4
Consolidated Statements of Equity - USD ($)
shares in Millions, $ in Millions
Total
Adoption of new accounting standards
 [1]
Common stock
Common stock
Adoption of new accounting standards
 [1]
Treasury stock
Treasury stock
Adoption of new accounting standards
 [1]
Additional paid-in capital
Additional paid-in capital
Adoption of new accounting standards
 [1]
Retained earnings
Retained earnings
Adoption of new accounting standards
 [1]
Accumulated other comprehensive loss
Accumulated other comprehensive loss
Adoption of new accounting standards
 [1]
Noncontrolling interest
Noncontrolling interest
Adoption of new accounting standards
 [1]
Beginning balance at Dec. 31, 2017 $ 5,097 $ (1,733) $ 18 $ 0 $ (11,923) $ 0 $ 14,270 $ 0 $ 5,459 $ (1,733) $ (2,727) $ 0 $ 0 $ 0
Beginning balance (in shares) at Dec. 31, 2017     1,592                      
Increase (Decrease) in Stockholders' Equity                            
Net earnings attributable to AbbVie Inc. 5,687   $ 0   0   0   5,687   0   0  
Other comprehensive income, net of tax 247   0   0   0   0   247   0  
Dividends declared (6,045)   0   0   0   (6,045)   0   0  
Purchases of treasury stock (12,215)   $ 0   (12,215)   0   0   0   0  
Purchases of treasury stock (in shares)     (121)                      
Stock-based compensation plans and other 516   $ 0   30   486   0   0   0  
Stock-based compensation plans and other (in shares)     8                      
Ending balance at Dec. 31, 2018 (8,446)   $ 18   (24,108)   14,756   3,368   (2,480)   0  
Ending balance (in shares) at Dec. 31, 2018     1,479                      
Increase (Decrease) in Stockholders' Equity                            
Net earnings attributable to AbbVie Inc. 7,882   $ 0   0   0   7,882   0   0  
Other comprehensive income, net of tax (1,116)   0   0   0   0   (1,116)   0  
Dividends declared (6,533)   0   0   0   (6,533)   0   0  
Purchases of treasury stock (428)   $ 0   (428)   0   0   0   0  
Purchases of treasury stock (in shares)     (5)                      
Stock-based compensation plans and other 469   $ 0   32   437   0   0   0  
Stock-based compensation plans and other (in shares)     5                      
Ending balance at Dec. 31, 2019 (8,172)   $ 18   (24,504)   15,193   4,717   (3,596)   0  
Ending balance (in shares) at Dec. 31, 2019     1,479                      
Increase (Decrease) in Stockholders' Equity                            
Net earnings attributable to AbbVie Inc. 4,616   $ 0   0   0   4,616   0   0  
Other comprehensive income, net of tax 479   0   0   0   0   479   0  
Dividends declared (8,278)   0   0   0   (8,278)     0  
Purchases of treasury stock (978)   $ 0   (978)   0   0   0   0  
Purchases of treasury stock (in shares)     (10)                      
Common shares and equity awards issued for acquisition of Allergan plc 24,409   $ 0   23,166   1,243   0   0   0  
Common shares and equity awards issued for acquisition of Allergan plc (in shares)     286                      
Stock-based compensation plans and other 1,000   $ 0   52   948   0   0   0  
Stock-based compensation plans and other (in shares)     10                      
Change in noncontrolling interest 21   $ 0   0   0   0   0   21  
Ending balance at Dec. 31, 2020 $ 13,097   $ 18   $ (2,264)   $ 17,384   $ 1,055   $ (3,117)   $ 21  
Ending balance (in shares) at Dec. 31, 2020     1,765                      
[1] Adoption of new accounting standards primarily includes the cumulative-effect adjustment of Accounting Standards Update (ASU) No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.